Abstract
Retinoblastoma (RB) is a pediatric retinal tumor that overexpresses the ganglioside GD2. Although it is treatable in patients with early diagnosis, patients may lose one or two eyes. We generated GD2-specific chimeric antigen receptor T lymphocytes (GD2.CAR-Ts) and locally delivered them to mice with an in situ grafting RB. We showed that, when used in combination with the local release of interleukin-15 and an injectable hydrogel, GD2.CAR-Ts successfully eliminate RB tumor cells without impairing mouse vision.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 /Â 30Â days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
BLI and imaging data can be found at figshare (https://figshare.com/articles/IVIS1_tif/12485699). All other data supporting the findings of this study are available from the corresponding author on reasonable request. Source data are provided with this paper.
References
Friend, S. H. et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323, 643–646 (1986).
Abramson, D. H., Shields, C. L., Munier, F. L. & Chantada, G. L. Treatment of retinoblastoma in 2015: agreement and disagreement. JAMA Ophthalmol. 133, 1341–1347 (2015).
Dimaras, H. et al. Retinoblastoma. Lancet 379, 1436–1446 (2012).
Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
Laurent, V. E. et al. Optimization of molecular detection of GD2 synthase mRNA in retinoblastoma. Mol. Med. Rep. 3, 253–259 (2010).
Pule, M. A. et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14, 1264–1270 (2008).
Yu, A. L. et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363, 1324–1334 (2010).
Gao, R et al. Developing nanoceria-based pH-dependent cancer-directed drug delivery system for retinoblastoma. Adv. Funct. Mater. 28, 1806248 (2018).
Waldmann, T. A., Dubois, S. & Tagaya, Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14, 105–110 (2001).
Chen, Y. et al. Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15. Clin. Cancer Res. 25, 2915–2924 (2019).
Wang, C. et al. In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy. Sci. Transl. Med. 10, eaan3682 (2018).
Monette, A., Ceccaldi, C., Assaad, E., Lerouge, S. & Lapointe, R. Chitosan thermogels for local expansion and delivery of tumor-specific T lymphocytes towards enhanced cancer immunotherapies. Biomaterials 75, 237–249 (2016).
Highton, A. J., Kojarunchitt, T., Girardin, A., Hook, S. & Kemp, R. A. Chitosan hydrogel vaccine generates protective CD8 T cell memory against mouse melanoma. Immunol. Cell Biol. 93, 634–640 (2015).
Heczey, A. et al. CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Mol. Ther. 25, 2214–2224 (2017).
Hoyos, V. et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24, 1160–1170 (2010).
Atik, A. F. et al. Hyaluronic acid based low viscosity hydrogel as a novel carrier for convection enhanced delivery of CAR T cells. J. Clin. Neurosci. 56, 163–168 (2018).
Tsao, C. T. et al. Thermoreversible poly(ethylene glycol)-g-chitosan hydrogel as a therapeutic T lymphocyte depot for localized glioblastoma immunotherapy. Biomacromolecules 15, 2656–2662 (2014).
Dunn, Z. S., Mac, J. & Wang, P. T cell immunotherapy enhanced by designer biomaterials. Biomaterials 217, 119265 (2019).
Wang, K., Lin, S., Nune, K. C. & Misra, R. D. Chitosan-gelatin-based microgel for sustained drug delivery. J. Biomater. Sci. Polym. Ed. 27, 441–453 (2016).
Wang, K., Nune, K. C. & Misra, R. D. The functional response of alginate-gelatin-nanocrystalline cellulose injectable hydrogels toward delivery of cells and bioactive molecules. Acta Biomater. 36, 143–151 (2016).
Ramos, C. A. et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J. Clin. Invest. 127, 3462–3471 (2017).
Ramos, C. A. et al. Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J. Clin. Invest. 126, 2588–2596 (2016).
Liang, K. J. et al. AAV-Nrf2 promotes protection and recovery in animal models of oxidative stress. Mol. Ther. 25, 765–779 (2017).
Stephan, S. B. et al. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat. Biotechnol. 33, 97–101 (2015).
Acknowledgements
We thank C. Shields and Shields & Shields Oncology (Philadelphia, PA) for providing human RB samples and D. Hill (the University of North Carolina at Chapel Hill) for providing access to a rheometer. We thank R. Hurwitz (Texas Children’s Hospital in Houston) for helpful discussions and comments on the manuscript. We appreciate financial support from the US National Eye Institute (R01EY026564, Z.H.), the Carolina Center of Cancer Nanotechnology Excellence (Z.H.), the NC TraCS Translational Research Grant (550KR151611, Z.H.), the Edward N. & Della L. Thome Memorial Foundation (138289, Z.H.), the BrightFocus Foundation (M2019063, Z.H.), the National Cancer Institute (1R21CA226483-01A1, G.D.) and the University Cancer Research Fund (UCRF, G.D.).
Author information
Authors and Affiliations
Contributions
K.W., G.D., B.S. and Z.H. designed the project. K.W., Y.C., S.A., M.Z. and E.L. conducted experiments and wrote the manuscript. K.W., Y.C., S.A., M.Z., E.L., B.S. and Z.H. contributed to the protocols and analyzed the data. G.D., B.S. and Z.H. edited the grammar and critically reviewed the manuscript. G.D., B.S. and Z.H. supervised the project. The manuscript was reviewed by all of the authors.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data
Extended Data Fig. 1 T cells expressed CAR and effector-tumor coculture exhibited elevated cytokine release.
a, CAR expression in T cells transduced with retroviral vectors encoding GD2.CAR, CD19.CAR, GD2.CAR.IL15, and CD19.CAR.IL15. CAR expression was evaluated by flow cytometry. b, IL-2 and IFN-γ released in the culture supernatants of CAR-Ts co-cultured with tumor cells. Supernatant was collected at 24 hours and cytokines were measured by specific ELISA (E:T=1:5, n = 5 donor/group, E:T=1:2, n = 3 donor/group). Data presented show mean and SEM.
Extended Data Fig. 2 The morphologic and rheologic properties of Chitosan-PEG hydrogel.
a, Lyophilized injectable hydrogel was imaged by scanning electron microscopy. The image showed 63 um average pore diameter of the hydrogel (n=10 technical replicates). b, GD2.CAR-Ts labelled with eGFP-FFLuc were encapsulated into the hydrogel and visualized by florescence macroscopy (B). Assessment of the viscoelastic properties of the injectable hydrogel tested at 23 °C and 37 °C (n=10 technical replicates) c, Rheological test result of the chitosan-PEG injectable hydrogel and water/saline16 (n=10 technical replicates). Data presented show mean and SD.
Extended Data Fig. 3 Molecular characterization of chitosan-PEG hydrogel.
a, 1H NMR spectra of the chitosan and the chitosan-PEG hydrogel precursor and (b) molecular weight of Chitosan-PEG precursors measured by dynamics light scattering (n=12 technical replicates). Data presented show mean and SD.
Extended Data Fig. 4 CAR-Ts release from hydrogels and chitosan-PEG hydrogel encapsulated GD2.CAR-Ts effectively eliminated tumor.
a, Viability of CAR-Ts released from alginate-gelatin and chitosan-PEG injectable hydrogel (n =3 donor/group). b, CAR-T cell release profile from alginate-gelatin and chitosan-PEG injectable hydrogel (n =3 donors/group). RB tumor cell lines were co-cultured with GD2.CAR-Ts or CD19.CAR-Ts at the effector to tumor ratio of 1:1 (c) and 1:5 (d) for 7 days upon encapsulation with the hydrogels. All cells were collected and analyzed by flow cytometry to enumerate T cells and residual tumor cells in the culture (n =3 donors/group). Data presented show mean and SEM.
Extended Data Fig. 5 The hydrogel facilitates the antitumor activity of GD2.CAR-Ts.
a, Migration assay showing T cell migration and viability in the collagen gel (Fluorescence Green: Living cells, Red: Dead cells) on days 1 and 4.24 b, Western blotting analysis of the protein lysate of the dissected eyes at day 35 post-treatment to detect IL-15. The statistical significance was determined using one-way ANOVA with Tukey’s post hoc test (GD2.CAR.15 versus GD2.CAR.15 hydrogel) P=0.012. n=3 individual sample/group. Data presented as mean and SEM.
Extended Data Fig. 6 The Gating strategy and photography of mice.
a, Gating strategy to assess effector-tumor coculture (CD4+/CD8+ cells) and the presence of T cells (CD45+ cells) and RB tumor cells (GD2+ cells) in the posterior segment of the eye by flow cytometry. b, Photographs of representative nu/nu mice (n=15/group) 35 days after engraftment with the Y79-eGFP-FFLuc tumor cell line and receiving the indicated treatments.
Supplementary information
Source data
Source Data Fig. 1
Statistical source data.
Source Data Fig. 2
Statistical source data.
Source Data Fig. 3
Statistical source data.
Source Data Fig. 4
Statistical source data.
Source Data Fig. 5
Statistical source data.
Source Data Fig. 5
Unprocessed western blots.
Source Data Extended Data Fig. 1
Statistical source data.
Source Data Extended Data Fig. 4
Statistical source data.
Source Data Extended Data Fig. 5
Statistical source data.
Rights and permissions
About this article
Cite this article
Wang, K., Chen, Y., Ahn, S. et al. GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision. Nat Cancer 1, 990–997 (2020). https://doi.org/10.1038/s43018-020-00119-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-020-00119-y
This article is cited by
-
Lyophilized lymph nodes for improved delivery of chimeric antigen receptor T cells
Nature Materials (2024)
-
Biomaterials to enhance adoptive cell therapy
Nature Reviews Bioengineering (2024)
-
Drug delivery methods for cancer immunotherapy
Drug Delivery and Translational Research (2024)
-
3D printed hydrogel scaffolds combining glutathione depletion-induced ferroptosis and photothermia-augmented chemodynamic therapy for efficiently inhibiting postoperative tumor recurrence
Journal of Nanobiotechnology (2022)
-
Engineered hydrogels for mechanobiology
Nature Reviews Methods Primers (2022)